Article
[AML treatment strategy based on cytogenetic abnormalities and somatic mutations].
[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Oct 2015
Imai Yoichi
Abstract excerpt
In addition to morphological and histocytochemical analyses of acute myeloid leukemia (AML), data on cytogenetic abnormalities and somatic mutations are used for classification of AML. The risk stratification based on these examinations facilitates determining the treatment strategy for AML. Cytogenetic risk category definitions by the Southwest Oncology Group (SWOG), Cancer and Leukemia Group B (CALGB), and The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
